Current treatment of psoriatic arthritis: Update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis

Joint Bone Spine

Volumn 82, Issue 2, 2015, Pages 80-85

  Paccou, Julien ^a   Wendling, Daniel ^b  

^a UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^b Hôpital Saint Jacques   (France)

Author keywords

Methotrexate; Psoriatic arthritis; Remission; Spondyloarthritis; TNF antagonist

Indexed keywords

ADALIMUMAB; APREMILAST; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; HUMAN; MEDICAL SOCIETY; META ANALYSIS; PSORIATIC ARTHRITIS; REMISSION; REVIEW; RHEUMATOLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; SPONDYLARTHRITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL PRODUCTS; GLUCOCORTICOIDS; HUMANS; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924435120     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.05.003     Document Type: Short Survey

References (51)

1. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12.
2. Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012, 71:319-326.
3. Pham T., Fautrel B., Dernis E., et al. Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with ankylosing spondylitis and psoriatic arthritis: 2007 update. Joint Bone Spine 2007, 74:638-646.
4. Pham T., Bachelez H., Berthelot J.M., et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011, 78:15-85.
5. Kaltwasser J.P., Nash P., Gladman D., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004, 50:1939-1950.
6. Kingsley G.H., Kowalczyk A., Taylor H., et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012, 51:1368-1377.
7. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
8. Mease P.J., Kivitz A.J., Burch F.X., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
9. Mease P.J., Kivitz A.J., Burch F.X., et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2years of treatment with etanercept. J Rheumatol 2006, 33:712-721.
10. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
11. Antoni C.E., Kavanaugh A., van der Heijde D., et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869-876.
12. Kavanaugh A., Antoni C.E., Gladman D., et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038-1043.
13. Kavanaugh A., Krueger G.G., Beutler A., et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007, 66:498-505.
14. Van der Heijde D., Kavanaugh A., Gladman D., et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698-2707.
15. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289.
16. Kavanaugh A., McInnes I., Mease P., et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986.
17. Kavanaugh A., Van Der Heijde D., Gladman D., et al. Long-term radiographic outcome in psoriatic arthritis patients treated with golimumab: 104-week results from the GO-REVEAL study. Arthritis Rheum 2010, 62:S812.
18. Mease P.J., Fleischmann R., Deodhar A.A., et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014, 73:233-237.
19. Sterry W., Ortonne J.P., Kirkham B., et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double-blind multicentre trial. BMJ 2010, 340:c147.
20. Kristensen L.E., Gülfe A., Saxne T., et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008, 67:364-369.
21. Glintborg B., Østergaard M., Dreyer L., et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011, 63:382-390.
22. Fagerli K.M., Lie E., van der Heijde D., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:132-137.
23. Mease P., Collier D., Saunders K., et al. Biologic therapy, time to low disease activity, and effect of mono vs. background oral DMARD therapy among psoriatic arthritis patients in a US registry. Ann Rheum Dis 2013, 72:671.
24. Coates L.C., Fransen J., Helliwell P.S. Defining minimal disease activity in psoriatic arthritis: a proposed objective to target for treatment. Ann Rheum Dis 2010, 69:48-53.
25. Coates L.C., Helliwell P.S. Validation of minimal disease activity criteria for psoriatic arthritis using international trial data. Arthritis Care Res (Hoboken) 2010, 62:965-969.
26. Smolen J.S., Braun J., Dougados M., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73:6-16.
27. Coates L.C., Navarro-Coy N., Brown S., et al. The TICOPA protocol (Tight COntrol of Psoriatic Arthritis): a randomized controlled trial to compare intensive management versus standard care in early psoriatic arthritis. BMC Musculoskeletal Disord 2013, 14:101.
28. Baranauskaite A., Raffayova H., Kungurov N.V., et al. Infliximab plus methotrexate is superior to methotrexate alone in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis 2012, 71:541-548.
29. Di Minno M.N., Peluso R., Iervolino S., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013, 65:141-147.
30. Di Minno M.N., Peluso R., Iervolino S., et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis 2014, 73:1157-1162.
31. Delaunay C., Farrenq V., Marini-Portugal A., et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005, 32:2183-2185.
32. Conti F., Ceccarelli F., Marocchi E., et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007, 66:1393-1397.
33. Coates L.C., Cawkwell L.S., Ng N.W., et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008, 67:717-719.
34. Paccou J., Houvenagel E., Solau-Gervais E., et al. Efficacy in current practice of switching between anti-TNFα agents in spondyloarthropathies. Rheumatology (Oxford) 2011, 50:714-720.
35. Van den Bosch F., Manger B., Goupille P., et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010, 69:394-399.
36. Gladman D.D., ACCLAIM Study Investigators, Sampalis J.S., et al. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol 2010, 37:1898-1906.
37. Glintborg B., Ostergaard M., Krogh N.S., et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013, 65:1213-1223.
38. Fagerli K.M., Lie E., van der Heijde D., et al. Switching between TNF-inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 2013, 72:1840-1844.
39. Mease P., Genovese M.C., Gladstein G., et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011, 63:939-948.
40. Mease P.J., Genovese M.C., Gladstein G.S., et al. Abatacept (ABA) in the treatment of psoriatic arthritis (PsA): 12-month results of a phase II study. Arthritis Rheum 2010, 62:S802.
41. Mease P., Genovese G., Ritchlin C., et al. Rituximab in psoriatic arthritis: results of an open-label study. Ann Rheum Dis 2010, 69:116.
42. Jimenez-Boj E., Stamm T.A., Sadlonova M., et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012, 71:1868-1871.
43. Gottlieb A., Menter A., Mendelsohn A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633-640.
44. McInnes I.B., Kavanaugh A., Gottlieb A.B., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789.
45. Ritchlin C.T., Gottlieb A.B., McInnes I.B., et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64:S1080.
46. Schett G., Wollenhaupt J., Papp K., et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64:3156-3167.
47. Birbara C., Blanco F.J., Crowley J.J., et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial. Arthritis Rheum 2013, 72:678.
48. Birbara C., Blanco F.J., Crowley J.J., et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis including current skin involvement: results of a phase 3, randomized, controlled trial. Ann Rheum Dis 2013, 72:85.
49. Mease P.J., Genovese M.C., Greenwald M.W., et al. Efficacy of brodalumab, an anti-IL17R antibody, in subjects with psoriatic arthritis. Ann Rheum Dis 2013, 72:85.
50. McInnes I.B., Sieper J., Braun J., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomized, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2014, 73:349-356.
51. Coates L.C., Tillett W., Chandler D., et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology (Oxford) 2013, 52:1754-1757.